-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Oral and Poster Abstracts

Saturday, December 9, 2023

Saturday | Sunday | Monday | top

9:30 AM-11:00 AM

101. Red Cells and Erythropoiesis, Excluding Iron: Red Cells: Emerging Gene Regulatory Mechanisms in Erythroid Differentiation
113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Emerging Therapies for Sickle Cell Disease
321. Coagulation and Fibrinolysis: Basic and Translational: Coagulation Protein: Molecular Insights and Molecular Therapies
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Out of the Box: Acquired, Vascular and Other Neglected Bleeding Disorders
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Inflammation, Metabolism, and Stress
603. Lymphoid Oncogenesis: Basic: Mechanisms of Acute Lymphoblastic Leukemia Development and Progression
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Upcoming Therapies in Newly Diagnosed and Relapsed/Refractory AML
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Risk Refinement and Therapy Response
627. Aggressive Lymphomas: Clinical and Epidemiological: Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Rare Myeloproliferative Neoplasms: Unveiling Promising Pathways and Novel Therapies
641. Chronic Lymphocytic Leukemias: Basic and Translational: Molecular Determinants of CLL and Richter Transformation
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment
652. Multiple Myeloma: Clinical and Epidemiological: T Cell Redirecting Therapy Outcomes and Associated Complications
703. Cellular Immunotherapies: Basic and Translational: Overcoming Challenges in CAR-T Therapies Through Biological Insights
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Improving Outcomes by Reducing Transplant-Related Complications
802. Chemical Biology and Experimental Therapeutics: Novel Targets in Blood Disorders
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Reading the Blood: Generative and Discriminative AI in Hematology
902. Health Services and Quality Improvement – Lymphoid Malignancies: Making a Splash In Outcomes Data
904. Outcomes Research – Non-Malignant Conditions: Across the Age Spectrum: Thromboembolism Outcomes in Adult and Pediatric Patients

2:00 PM-3:30 PM

101. Red Cells and Erythropoiesis, Excluding Iron: Red Cells: Erythropoiesis in Stress and Disease
114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Hot Topics in Clinical Care and Genomic Factors
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Decoding the Complex Landscape of Human Immunity: Insights From Genetic Mutations to Cellular Heterogeneity
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Uses of Approved Therapeutic Agents
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Biomarkers and Therapeutics
621. Lymphomas: Translational – Molecular and Genetic: Microenvironment and Methylome in Lymphoma and Misc.
622. Lymphomas: Translational – Non-Genetic: Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma
624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Topics in T Cell, Szary and Hodgkin Lymphomas
627. Aggressive Lymphomas: Clinical and Epidemiological: Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment Options and Decision Making in Low Risk MDS
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation
653. Multiple Myeloma: Prospective Therapeutic Trials: Smoldering and Newly Diagnosed Myeloma
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Screening to Vaccines–The Spectrum of Plasma Cell Disorders
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Expanding Disease Targets for CAR-T Cell Therapies
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Translational Data and Prognostic Factors
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia
723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Long-Term Survival and Survivorship From Clinical Trials And Observations
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Emerging Technologies for Understanding Benign and Malignant Hematology
901. Health Services and Quality Improvement – Non-Malignant Conditions: Sickle Cell Disease Across the Spectrum
902. Health Services and Quality Improvement – Lymphoid Malignancies: Innovative Care in CAR-T Therapy
903: Health Services and Quality Improvement – Myeloid Malignancies: From Blood to Bombs: Identifying and Addressing Barriers to Care for Myeloid Malignancies
905. Outcomes Research – Lymphoid Malignancies: Outcomes Research in Lymphoma/CLL: Biomarkers, Dosing Strategies, and Big-Data

4:00 PM-5:30 PM

114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Beyond the Numbers: Non-Factor Factors in Bleeding Disorder Care
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Immunologic and Metabolic Biomarkers of Disease Control
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL
624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Advances in Treating T Cell Lymphomas
627. Aggressive Lymphomas: Clinical and Epidemiological: Outcomes of Relapsed/Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents
636. Myelodysplastic Syndromes – Basic and Translational: Molecular Drivers and Therapeutic Implications
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatments and Outcome Predictions in High Risk MDS
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterization of the MM and the Tumor Microenvironment
652. Multiple Myeloma: Clinical and Epidemiological: Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics
701. Experimental Transplantation: Basic and Translational: GVHD, Intestinal Immunity, and the Gut Microbiome
703. Cellular Immunotherapies: Basic and Translational: Cellular Immunotherapy: Preclinical and Translational Insights
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Prediction and Management of CAR-T Cell Related Toxicity
723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Basic and Translational: Optimizing Post-Transplant Outcomes
901. Health Services and Quality Improvement – Non-Malignant Conditions: Access to Quality Care in Classical Hematology
903. Health Services and Quality Improvement – Myeloid Malignancies: Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies
905. Outcomes Research – Lymphoid Malignancies: Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma
906. Outcomes Research – Myeloid Malignancies: Risk Factors and Health Disparities

5:30 PM-7:30 PM

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I
102. Iron Homeostasis and Biology: Poster I
112. Thalassemia and Globin Gene Regulation: Poster I
113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I
114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I
201. Granulocytes, Monocytes, and Macrophages: Poster I
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I
321. Coagulation and Fibrinolysis: Basic and Translational: Poster I
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I
331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-Related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster I
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I
401. Blood Transfusion: Poster I
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I
503. Clonal Hematopoiesis, Aging and Inflammation: Poster I
506. Bone Marrow Microenvironment: Poster I
508. Bone Marrow Failure: Acquired: Poster I
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I
602. Myeloid Oncogenesis: Basic: Poster I
603. Lymphoid Oncogenesis: Basic: Poster I
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I
621. Lymphomas: Translational – Molecular and Genetic: Poster I
622. Lymphomas: Translational – Non-Genetic: Poster I
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I
624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Poster I
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I
627. Aggressive Lymphomas: Clinical and Epidemiological: Poster I
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I
636. Myelodysplastic Syndromes – Basic and Translational: Poster I
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster I
641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster I
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I
652. Multiple Myeloma: Clinical and Epidemiological: Poster I
653. Multiple Myeloma: Prospective Therapeutic Trials: Poster I
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I
701. Experimental Transplantation: Basic and Translational: Poster I
703. Cellular Immunotherapies: Basic and Translational: Poster I
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I
711. Cell Collection and Processing: Poster I
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I
723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Poster I
731. Autologous Transplantation: Clinical and Epidemiological: Poster I
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
801. Gene Therapies: Poster I
802. Chemical Biology and Experimental Therapeutics: Poster I
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster I
901. Health Services and Quality Improvement – Non-Malignant Conditions: Poster I
902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster I
903. Health Services and Quality Improvement – Myeloid Malignancies: Poster I
904. Outcomes Research – Non-Malignant Conditions: Poster I
905. Outcomes Research – Lymphoid Malignancies: Poster I
906. Outcomes Research – Myeloid Malignancies: Poster I

Sunday, December 10, 2023

Saturday | Sunday | Monday | top

9:30 AM-11:00 AM

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Clinical Practice, Natural History, and Patient Reported Outcomes
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Cell Fate Decisions and Fitness
602. Myeloid Oncogenesis: Basic: Therapeutic Strategies and Cellular Mechanisms
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Strategies to Overcome Therapy Resistance in Myeloid Malignancies
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeted Therapy in Lymphoid Leukemias
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease and Therapy Response
622. Lymphomas: Translational – Non-Genetic: Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Novel Therapies For Relapsed/Refractory Aggressive Lymphoma
627. Aggressive Lymphomas: Clinical and Epidemiological: Treatment to Best Outcomes: Find the Right Therapy for the Right Patient
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Treatment-Free Remission and Prognostication
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterizing Response and Resistance to CAR-T and TCEs
701. Experimental Transplantation: Basic and Translational: T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution
703. Cellular Immunotherapies: Basic and Translational: Novel Approaches for Next Generation Cellular Immunotherapies
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Novel Conditioning Regimens for Myeloid Malignancies
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Emerging Insights in GVHD Immunobiology
801. Gene Therapies: New Approaches From Bench to Bedside
904. Outcomes Research – Non-Malignant Conditions: What to Know: Management Costs and Outcomes in Various Non-Malignant Disorders
905. Outcomes Research – Lymphoid Malignancies: Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology

12:00 PM-1:30 PM

301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Bleeding Disorder Management Throughout the Lifespan
506. Bone Marrow Microenvironment: Bone Marrow Microenvironment in Health and Disease
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Progress Through Collaboration: Impactful Cooperative Efforts to Optimize Care for ALL
621. Lymphomas: Translational – Molecular and Genetic: Signaling Pathways and MRD in Lymphoma
652. Multiple Myeloma: Clinical and Epidemiological: Outcomes, Choices and Predispositions
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril–Novel Diagnostics to Treatments for Amyloidosis
905. Outcomes Research – Lymphoid Malignancies: Outcomes Research in Myeloma: What's New?
906. Outcomes Research – Myeloid Malignancies: Real-World Treatment Patterns and Outcomes

4:30 PM-6:00 PM

112. Thalassemia and Globin Gene Regulation: Finding New Pathways to Treat Thalassemia
113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Pathophysiology of Sickle Hemoglobinopathies: From Mice to Humans
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT): Understanding Risk as a Potential Means to Improve Patient Care
508. Bone Marrow Failure: Acquired: Unraveling the Future of PNH Therapy From Clinical Trials
602. Myeloid Oncogenesis: Basic: Chemical and Genetic Approaches for Targeting Leukemic Stem Cells
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Real World Outcomes and Treatment Approaches
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Targeted Therapies and The Immune Microenvironment
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Immunotherapy
624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Advances in the Treatment of Hodgkin Lymphoma
627. Aggressive Lymphomas: Clinical and Epidemiological: Aiming for the Right Target: Using CAR-T and Bispecifics in Aggressive Lymphomas
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Charting The Future Of MPN Therapies
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Myelofibrosis: New Therapeutic Frontiers
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Molecular Characterization of MM and Precursor Disease States
652. Multiple Myeloma: Clinical and Epidemiological: Novel Biomarkers for Treatment Guidance in Multiple Myeloma
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Innovative Approaches to GVHD Prevention and Treatment
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Use of Molecular Techniques for Risk Stratification
901. Health Services and Quality Improvement – Non-Malignant Conditions: Raising the bar in Anemia, Bleeding, and Thrombotic Disorders
905. Outcomes Research – Lymphoid Malignancies: Patient Reported Outcomes in Hematological Malignancies

6:00 PM-8:00 PM

101. Red Cells and Erythropoiesis, Excluding Iron: Poster II
102. Iron Homeostasis and Biology: Poster II
112. Thalassemia and Globin Gene Regulation: Poster II
113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II
114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster II
201. Granulocytes, Monocytes, and Macrophages: Poster II
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster II
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II
321. Coagulation and Fibrinolysis: Basic and Translational: Poster II
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II
331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster II
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II
401. Blood Transfusion: Poster II
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II
503. Clonal Hematopoiesis, Aging and Inflammation: Poster II
506. Bone Marrow Microenvironment: Poster II
508. Bone Marrow Failure: Acquired: Poster II
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II
602. Myeloid Oncogenesis: Basic: Poster II
603. Lymphoid Oncogenesis: Basic: Poster II
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
621. Lymphomas: Translational—Molecular and Genetic: Poster II
622. Lymphomas: Translational–Non-Genetic: Poster II
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II
627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
636. Myelodysplastic Syndromes—Basic and Translational: Poster II
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster II
641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster II
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II
652. Multiple Myeloma: Clinical and Epidemiological: Poster II
653. Multiple Myeloma: Prospective Therapeutic Trials: Poster II
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II
701. Experimental Transplantation: Basic and Translational: Poster II
703. Cellular Immunotherapies: Basic and Translational: Poster II
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II
711. Cell Collection and Processing: Poster II
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster II
731. Autologous Transplantation: Clinical and Epidemiological: Poster II
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
801. Gene Therapies: Poster II
802. Chemical Biology and Experimental Therapeutics: Poster II
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster II
901. Health Services and Quality Improvement - Non-Malignant Conditions: Poster II
902. Health Services and Quality Improvement - Lymphoid Malignancies: Poster II
903. Health Services and Quality Improvement –Myeloid Malignancies: Poster II
904. Outcomes Research—Non-Malignant Conditions: Poster II
905. Outcomes Research—Lymphoid Malignancies: Poster II
906. Outcomes Research—Myeloid Malignancies: Poster II

Monday, December 11, 2023

Saturday | Sunday | Monday | top

10:30 AM-12:00 PM

201. Granulocytes, Monocytes, and Macrophages: Granulocytes, Monocytes and Disorders of Histocytes
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Targeting platelet reactivity in thrombosis
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Innovative Treatments for Immune Thrombocytopenia
331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-Related Thrombotic/Vascular Disorders: Clinical and Epidemiological: New Frontiers in TTP: Diagnostic and Therapeutic Innovations
401. Blood Transfusion: Advances in Transfusion Medicine
508. Bone Marrow Failure: Acquired: Immune AA and VEXAS – Biology, Diagnosis and Treatment
602. Myeloid Oncogenesis: Basic: RNA Splicing, Transcription, and Chromatin Dynamics
603. Lymphoid Oncogenesis: Basic: Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Innovations in Prognostication
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Long-Term Outcomes for Children and Adults Diagnosed With AML/APL
623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stromal-Immune and Signaling Context
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Treatment and Outcomes in MPNs
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Advancing Therapies in Multiple Myeloma and Waldenström's Macroglobulinemia
652. Multiple Myeloma: Clinical and Epidemiological: Immunological Effects of Sustained Responses in Multiple Myeloma
703. Cellular Immunotherapies: Basic and Translational: Exploring Novel Platforms for Next-Gen CAR-Based Therapies
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Advancements in GVHD Management
731. Autologous Transplantation: Clinical and Epidemiological: Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas: A Therapeutic Approach
901. Health Services and Quality Improvement – Non-Malignant Conditions: Improving Care in Sickle Cell Disease Via Technologies and Medical Education

2:45 PM-4:15 PM

114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advances in Clinical Care and Implementation
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Thrombocytopenia in Special Populations
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Genetics, Pregnancy, and Pediatrics: Advances in Venous Thromboembolism
503. Clonal Hematopoiesis, Aging and Inflammation: From Omics to Discoveries
613. Acute Myeloid Leukemias: Clinical and Epidemiological: AML – De Novo and Myelodysplasia-Related
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Optimal Frontline Treatment for ALL
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Refining Chemotherapy Regimens Plus/Minus MRD Evaluation to Optimize Outcomes in AML
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Deciphering Risk by Genetic and Epigenetic Features
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Novel Disease Subclassifications and Clinical Prognosis
621. Lymphomas: Translational – Molecular and Genetic: Insights into Lymphoma: Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Initial treatment strategies in aggressive B Cell lymphomas
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Lineage Tracing and Novel Target Discovery
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions
652. Multiple Myeloma: Clinical and Epidemiological: Molecular and Biological Signatures and Predictors of Outcomes
703. Cellular Immunotherapies: Basic and Translational: Innovative T Cell Therapies for Unexplored Frontiers
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Improving CAR-T Therapies for B Cell Malignancies
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Modern Challenges in Transplantation
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Image-Based Machine Learning in Hematology
902. Health Services and Quality Improvement – Lymphoid Malignancies: Improving Processes and Outcomes in Plasma Cell Dyscrasias
906. Outcomes Research – Myeloid Malignancies: Symptom Burden and Supportive Therapies

4:30 PM-6:00 PM

102. Iron Homeostasis and Biology: Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis
114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Sickle Cell Treatment: Present and Future
201. Granulocytes, Monocytes, and Macrophages: New Insights into Inherited and Acquired Neutropenias
503. Clonal Hematopoiesis, Aging and Inflammation: Translational Innovations
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital and Misc.
602. Myeloid Oncogenesis: Basic: Mechanisms and Models of Myeloid Malignancy
613. Acute Myeloid Leukemias: Clinical and Epidemiological: AML– Molecular Targets, Ethnicity, and AI
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Therapies for ALL
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Improving Intensive Chemotherapy Regimens for Treatment of AML
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Response Predictors to Targeted Therapies and Transplant
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Targeted Therapy
627. Aggressive Lymphomas: Clinical and Epidemiological: Uncommon Aggressive NHL
631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Oncogenic Drivers and Genetic Models
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Genomic Classification and Prognostication of MDS
652. Multiple Myeloma: Clinical and Epidemiological: Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma
653. Multiple Myeloma: Prospective Therapeutic Trials: Relapsed and Refractory Myeloma
703. Cellular Immunotherapies: Basic and Translational: Evaluating Strategies to Enhance Cellular Immunotherapies
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas: Clinical Trial and Real World Evidence
711. Cell Collection and Processing: Hematopoietic Stem/Progenitor Cells Graft and Immune Effector Cells
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Expanding the Donor Pool
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Donor and Conditioning Regimen Selection
801. Gene Therapies: The Long and the Short of Clinical Trials in Blood Disorders
904. Outcomes Research – Non-Malignant Conditions: Blending the Old With the New: Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease
905. Outcomes Research – Lymphoid Malignancies: Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma

6:00 PM-8:00 PM

101. Red Cells and Erythropoiesis, Excluding Iron: Poster III
102. Iron Homeostasis and Biology: Poster III
112. Thalassemia and Globin Gene Regulation: Poster III
113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III
114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III
201. Granulocytes, Monocytes, and Macrophages: Poster III
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster III
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III
321. Coagulation and Fibrinolysis: Basic and Translational: Poster III
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III
331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster III
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III
401. Blood Transfusion: Poster III
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III
503. Clonal Hematopoiesis, Aging and Inflammation: Poster III
506. Bone Marrow Microenvironment: Poster III
508. Bone Marrow Failure: Acquired: Poster III
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III
602. Myeloid Oncogenesis: Basic: Poster III
603. Lymphoid Oncogenesis: Basic: Poster III
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III
621. Lymphomas: Translational—Molecular and Genetic: Poster III
622. Lymphomas: Translational–Non-Genetic: Poster III
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III
627. Aggressive Lymphomas: Clinical and Epidemiological: Poster III
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
636. Myelodysplastic Syndromes—Basic and Translational: Poster III
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster III
641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster III
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III
652. Multiple Myeloma: Clinical and Epidemiological: Poster III
653. Multiple Myeloma: Prospective Therapeutic Trials: Poster III
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III
701. Experimental Transplantation: Basic and Translational: Poster III
703. Cellular Immunotherapies: Basic and Translational: Poster III
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III
711. Cell Collection and Processing: Poster III
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster III
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III
731. Autologous Transplantation: Clinical and Epidemiological: Poster III
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
801. Gene Therapies: Poster III
802. Chemical Biology and Experimental Therapeutics: Poster III
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster III
901. Health Services and Quality Improvement - Non-Malignant Conditions: Poster III
902. Health Services and Quality Improvement - Lymphoid Malignancies: Poster III
903. Health Services and Quality Improvement –Myeloid Malignancies: Poster III
904. Outcomes Research—Non-Malignant Conditions: Poster III
905. Outcomes Research—Lymphoid Malignancies: Poster III
906. Outcomes Research—Myeloid Malignancies: Poster III